What Is Ipamorelin?
The cleanest growth hormone releasing peptide available — significant GH pulse amplification with minimal cortisol, prolactin, or appetite side effects.
Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue — specifically a ghrelin receptor agonist (GHS-R1a agonist) developed by Novo Nordisk in the 1990s. It belongs to the Growth Hormone Releasing Peptide (GHRP) family — compounds that stimulate GH release through the ghrelin receptor pathway, which is entirely separate from the GHRH receptor pathway that CJC-1295 and Sermorelin use.
What distinguishes Ipamorelin within the GHRP class is its selectivity. Earlier GHRPs — GHRP-2 and GHRP-6 — produce significant GH release but come with meaningful side effects: GHRP-6 causes substantial appetite stimulation and cortisol elevation; GHRP-2 causes significant cortisol and prolactin elevation. Ipamorelin produces robust GH release with minimal cortisol elevation, minimal prolactin elevation, and minimal appetite stimulation — making it the most favorable side effect profile of any GHRP available.
Ipamorelin is almost never used alone. Its power lies in its synergy with GHRH analogs — when combined with CJC-1295 or Sermorelin, the two compounds work through complementary receptor pathways to produce GH pulses significantly larger than either could produce independently. The CJC-1295 + Ipamorelin combination has become the most widely used GH optimization stack in functional medicine.
GHRP-6 produces strong GH release but also causes significant hunger (via ghrelin receptor activation in the hypothalamus) and cortisol elevation. GHRP-2 produces the strongest GH release of any GHRP but with the highest cortisol and prolactin elevation. Ipamorelin hits the sweet spot — meaningful GH release with minimal off-target effects. For longevity and anti-aging protocols where cortisol management and body composition are priorities, Ipamorelin's clean profile makes it the first choice GHRP by a significant margin.
How Does Ipamorelin Work?
Four mechanisms explain Ipamorelin's selective GH-stimulating and downstream anti-aging effects.
Ipamorelin binds selectively to the GHS-R1a receptor — the ghrelin receptor — on pituitary somatotroph cells. This triggers GH release through a calcium-dependent mechanism that is entirely independent of the GHRH receptor pathway. This receptor independence is why Ipamorelin and CJC-1295 are synergistic — they activate GH release through two completely different molecular switches simultaneously.
Ipamorelin's selectivity is its defining characteristic. Unlike other GHRPs that also activate receptors for ACTH (driving cortisol) and prolactin release, Ipamorelin's binding profile is highly selective for the GH-secreting pathway. The result is clean GH pulse amplification without the cortisol, prolactin, and appetite side effects that limit other GHRPs' utility in longevity protocols.
Ipamorelin partially suppresses somatostatin — the hormone that inhibits GH release. This dual action (stimulating GH release while reducing the signal that inhibits it) is one reason the GH pulse produced by Ipamorelin is significantly amplified when combined with a GHRH analog. The GHRH signal pushes the accelerator; Ipamorelin also releases the brake.
Like all GH secretagogues, Ipamorelin's effects are largely mediated through the GH it stimulates the pituitary to release — which then signals the liver to produce IGF-1. Elevated IGF-1 drives muscle protein synthesis, fat metabolism, bone density maintenance, collagen production, and tissue repair — the downstream benefits that make GH optimization meaningful for aging adults.
What Is Ipamorelin Used For?
Body composition, sleep, recovery, and anti-aging — the downstream benefits of restored GH pulsatility.
- Body Composition — Lean Muscle & Fat LossThe most commonly sought benefit. Ipamorelin-driven GH and IGF-1 elevation supports lean muscle maintenance and growth while enhancing fat metabolism. Most meaningful when combined with CJC-1295 for amplified GH pulses — the combination produces body composition results that neither achieves alone at standard doses.
- Deep Sleep QualityThe nocturnal GH pulse — amplified by pre-bed Ipamorelin + CJC-1295 administration — produces measurable improvements in slow-wave sleep depth and duration. Many users report this as the earliest and most noticeable benefit — often within the first 1–2 weeks of consistent nightly dosing.
- Recovery & Tissue RepairGH and IGF-1 are primary drivers of tissue repair — accelerating recovery from training, injury, and surgical procedures. Post-workout Ipamorelin dosing is used by athletes to amplify the natural GH pulse that follows intense exercise, enhancing recovery and adaptation.
- Anti-Aging & LongevityGH declines approximately 50% between ages 20 and 60 — contributing to the body composition changes, sleep deterioration, cognitive decline, and reduced vitality that characterize biological aging. Ipamorelin addresses this upstream hormonal decline in the context of a comprehensive longevity protocol.
- Bone DensityGH and IGF-1 are critical regulators of bone metabolism. Ipamorelin-driven GH optimization supports bone density maintenance — particularly relevant for post-menopausal women and men over 50 where age-related bone density decline accelerates.
- Skin & CollagenIGF-1 stimulates fibroblast activity and collagen synthesis — contributing to improved skin thickness, elasticity, and wound healing. A meaningful complement to GHK-Cu's direct collagen gene regulation for comprehensive skin anti-aging.
Ipamorelin vs Other GHRPs
Why Ipamorelin has become the preferred GHRP for longevity and anti-aging protocols.
| Feature | Ipamorelin | GHRP-2 | GHRP-6 |
|---|---|---|---|
| GH release | Strong Good | Strongest | Strong |
| Cortisol elevation | Minimal ✅ Best | Significant ❌ | Moderate ⚠️ |
| Prolactin elevation | Minimal ✅ Best | Significant ❌ | Moderate ⚠️ |
| Appetite stimulation | Minimal ✅ Best | Moderate ⚠️ | Strong ❌ |
| Selectivity | Highly selective Best | Less selective | Less selective |
| Best for longevity | ✅ First choice | ⚠️ Side effects limit use | ⚠️ Hunger problematic |
| Stack with GHRH? | ✅ Essential — always stack | ✅ Yes | ✅ Yes |
How to Use Ipamorelin
Always combined with a GHRH analog — the synergy is the point.
Ipamorelin must be administered in a fasted state. Insulin — elevated after eating, particularly carbohydrates — directly suppresses GH release through somatostatin activation. Administering Ipamorelin in a fed state dramatically reduces the GH pulse produced. Allow a minimum of 2 hours after your last meal. Pre-bed administration is optimal because it aligns with the overnight fast and amplifies the natural nocturnal GH pulse.
Ipamorelin in a Longevity Stack
Ipamorelin is always the GHRP component — paired with a GHRH analog and complementary longevity compounds.
- +Ipamorelin + CJC-1295 — The definitive pairing. CJC-1295 activates the GHRH receptor on pituitary somatotrophs; Ipamorelin simultaneously activates the ghrelin receptor. These are completely independent molecular pathways that both trigger GH release — firing both at once produces synergistic GH pulses 2–3x larger than either compound alone. This is the most widely used GH optimization combination in functional medicine and the standard by which other GH protocols are measured.
- +Ipamorelin + Sermorelin — A more conservative alternative to the CJC-1295 combination — using Sermorelin's FDA history and established track record as the GHRH component rather than CJC-1295. Produces a smaller but still synergistic GH pulse. Preferred by practitioners who prioritize the more extensively documented safety profile of Sermorelin for first-time GH secretagogue users.
- +Ipamorelin + Epithalon — Epithalon restores pineal-hypothalamic-pituitary axis coordination — the upstream regulatory system for the nocturnal GH pulse. Ipamorelin amplifies that pulse at the pituitary level via ghrelin receptor activation. Together they address GH restoration from the regulatory (Epithalon) and amplification (Ipamorelin) angles — with particular synergy for sleep quality, where both compounds independently improve deep sleep architecture.
- +Ipamorelin + AOD 9604 — A targeted body composition combination. Ipamorelin drives the GH pulse that supports muscle maintenance and overall body composition; AOD 9604 specifically amplifies the lipolytic (fat burning) component of GH signaling without the tissue growth or insulin effects of full GH. Together they address body composition from the systemic GH optimization (Ipamorelin) and targeted fat metabolism (AOD 9604) angles simultaneously.
Frequently Asked Questions
Technically yes — Ipamorelin does produce GH release on its own. But the synergy with a GHRH analog is so significant that most practitioners consider it suboptimal to use Ipamorelin alone. The GH pulse produced by Ipamorelin + CJC-1295 is 2–3x larger than Ipamorelin alone at the same dose. If CJC-1295 is unavailable, Sermorelin is an acceptable alternative GHRH partner. Using Ipamorelin alone is somewhat like using half a compound — it works, but misses the point of how the compound is designed to function.
Minimally — this is one of Ipamorelin's key advantages. GHRP-6 causes significant hunger because it strongly activates ghrelin receptors in the hypothalamus (hunger center) in addition to pituitary GH release. Ipamorelin's more selective binding profile produces meaningful GH release with minimal hypothalamic ghrelin activation. Some users report mild hunger, particularly at higher doses — but it is substantially less than GHRP-6 and not a meaningful concern at standard protocol doses.
Sleep improvement is typically the earliest noticeable benefit — often within 1–2 weeks of consistent nightly dosing. Energy and recovery improvements follow at 2–4 weeks. Body composition changes — fat reduction, improved muscle definition — become measurable at 3–6 months with consistent protocol adherence, appropriate nutrition, and progressive training. GH optimization is a long-term intervention; patience and consistency are essential.
Not significantly at standard protocol doses with appropriate cycling. Ipamorelin works within the natural feedback loop — the GH and IGF-1 it stimulates activate somatostatin to prevent excess. Standard cycling (5 days on / 2 days off, with periodic longer breaks of 4–6 weeks every 3–4 months) is used as an additional precaution. Long-term continuous use without breaks is generally avoided — not because of established suppression risk, but as conservative good practice.
IGF-1 is the primary marker — test at baseline before starting, at 3 months, and at 6 months. Target range is typically 200–300 ng/mL for most adults — your provider will set age-appropriate targets. Also monitor fasting glucose and fasting insulin — GH elevation can affect insulin sensitivity at high levels. A comprehensive metabolic panel at baseline and 6 months provides useful context. Never push IGF-1 above the upper limit of your age-appropriate reference range.
Instant PDF download
This page is for educational purposes only and does not constitute medical advice. Ipamorelin is not FDA-approved for any indication. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol. Regular IGF-1 monitoring under physician supervision is standard practice for GH secretagogue protocols. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.
What Is CJC-1295?
A modified GHRH analog that stimulates the pituitary to produce growth hormone — with significantly longer action than natural GHRH or Sermorelin.
CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) — the hypothalamic signal that triggers the pituitary gland to release growth hormone. It is based on the same first 29 amino acids of GHRH as Sermorelin, but with four key amino acid substitutions that dramatically increase its stability and half-life compared to both natural GHRH and Sermorelin.
CJC-1295 comes in two distinct variants that have meaningfully different pharmacokinetic profiles: CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) produces a pulsatile GH release pattern that mimics natural physiology. CJC-1295 with DAC (Drug Affinity Complex) binds to albumin in the bloodstream, extending its half-life from ~30 minutes to approximately 8 days — producing a prolonged "GH bleed" rather than a pulsatile pulse.
This variant distinction is one of the most important and most misunderstood aspects of CJC-1295 use. The choice between DAC and no-DAC has significant implications for how the compound affects GH physiology — and most practitioners in the longevity space now prefer the without DAC version for its more physiological pulsatile GH release pattern.
Both CJC-1295 (without DAC) and Sermorelin are GHRH analogs that stimulate pulsatile GH release. The key difference is half-life: Sermorelin has a half-life of ~10–20 minutes; CJC-1295 without DAC has a half-life of ~30 minutes. This longer window gives CJC-1295 a larger GH pulse amplitude per injection. Both preserve the natural feedback loop that prevents excess — making either a safer choice than exogenous HGH. CJC-1295 with DAC, by contrast, produces a sustained GH elevation for days — a fundamentally different and less physiological pattern.
How Does CJC-1295 Work?
Four mechanisms explain CJC-1295's GH-stimulating and downstream anti-aging effects.
CJC-1295 binds to GHRH receptors on pituitary somatotroph cells — triggering the release of stored growth hormone. This is the same receptor that natural GHRH activates, but CJC-1295's modified amino acid sequence makes it resistant to the dipeptidyl peptidase-IV (DPP-IV) enzyme that rapidly degrades natural GHRH. The result is a longer receptor activation window and larger GH pulse.
Growth hormone released by CJC-1295 stimulates the liver to produce IGF-1 — the primary downstream mediator of GH's anabolic and regenerative effects. Elevated IGF-1 drives muscle protein synthesis, fat metabolism, bone density maintenance, and tissue repair. Tracking IGF-1 levels is the standard way to assess CJC-1295 protocol efficacy.
The largest natural GH pulse occurs during slow-wave sleep. CJC-1295 administered before bed amplifies this nocturnal pulse — improving deep sleep quality and duration while maximizing the anabolic and regenerative benefits of nighttime GH secretion. This creates a positive feedback loop: better GH pulse → better sleep → better GH pulse the following night.
Like Sermorelin, CJC-1295 (without DAC) works within the natural GH feedback system. When GH and IGF-1 reach appropriate levels, somatostatin is released to inhibit further GH secretion — preventing excess. This self-regulating mechanism is absent with exogenous HGH and is one of the primary safety advantages of GHRH analogs over synthetic HGH.
CJC-1295 With DAC vs Without DAC
The most important distinction in CJC-1295 — two very different pharmacological profiles under one name.
| Feature | CJC-1295 Without DAC | CJC-1295 With DAC |
|---|---|---|
| Also known as | Modified GRF 1-29, Mod GRF 1-29 | CJC-1295 DAC |
| Half-life | ~30 minutes Physiological | ~8 days |
| GH release pattern | Pulsatile — mimics natural physiology Preferred | Sustained "GH bleed" |
| Injection frequency | Daily or 3x weekly | Once weekly Convenient |
| Feedback loop | ✅ Preserved — self-regulating | ⚠️ Partially bypassed |
| Preferred by | Most longevity practitioners Recommended | Some bodybuilding contexts |
| Best stacked with | Ipamorelin — daily before bed | Less commonly stacked |
| Practitioner consensus | First choice for anti-aging protocols | Less preferred — less physiological |
For anti-aging and longevity applications — CJC-1295 without DAC is the preferred choice. Its pulsatile GH release pattern mirrors natural physiology, preserves the feedback loop that prevents excess, and stacks synergistically with Ipamorelin for amplified pulsatile release. CJC-1295 with DAC's week-long sustained GH elevation is considered less physiological and is less commonly recommended by longevity-focused practitioners.
What Is CJC-1295 Used For?
The downstream effects of restored GH pulsatility touch virtually every system affected by aging.
- Body Composition — Muscle & FatThe most sought-after application. Restored GH and IGF-1 support lean muscle maintenance and growth while enhancing fat metabolism — particularly visceral fat reduction. Body composition improvements become measurable over 3–6 months of consistent protocol adherence combined with appropriate training and nutrition.
- Deep Sleep QualityOften the earliest and most noticeable benefit — users consistently report significantly improved sleep depth within the first 2–4 weeks. The nocturnal GH pulse amplification produces measurable improvements in slow-wave sleep architecture that cascade into energy, recovery, and cognitive function.
- Recovery & Tissue RepairGH and IGF-1 are critical drivers of tissue repair — accelerating recovery from exercise, injury, and surgical procedures. CJC-1295 is particularly popular among athletes and active adults for its recovery-enhancing effects alongside body composition benefits.
- Cognitive Function & EnergyGH receptors are present throughout the brain. Restored GH pulsatility supports neuronal health, mental clarity, and the energy levels that decline with age-related GH reduction. Many users report improved cognitive stamina and motivation alongside physical benefits.
- Skin & CollagenGH and IGF-1 stimulate collagen synthesis and skin cell turnover — supporting skin thickness, elasticity, and the reduction of fine lines associated with collagen loss. Particularly meaningful when combined with GHK-Cu for comprehensive skin anti-aging.
- Bone DensityGH and IGF-1 are critical regulators of bone metabolism and density — a key longevity consideration for adults over 45 facing age-related bone density decline. Particularly relevant for post-menopausal women where estrogen-dependent bone protection has declined.
How to Use CJC-1295
Almost always used in combination with Ipamorelin — the GHRH + GHRP synergy produces significantly larger GH pulses than either alone.
CJC-1295 must be administered in a fasted state — food intake, particularly carbohydrates and fats, elevates insulin which directly suppresses GH release. Administer at least 2 hours after your last meal and at least 30 minutes before eating. The nightly before-bed window is optimal because it aligns with the natural nocturnal GH pulse and the overnight fasted state. Never administer with or immediately after meals.
CJC-1295 vs Sermorelin vs Ipamorelin
Understanding the GH secretagogue landscape — GHRH analogs vs GHRPs and how they differ.
| Feature | CJC-1295 (no DAC) | Sermorelin | Ipamorelin |
|---|---|---|---|
| Type | GHRH analog | GHRH analog | GHRP (ghrelin mimetic) |
| Half-life | ~30 min Longer | ~10–20 min | ~2 hours |
| GH pulse size | Large Strongest GHRH | Moderate | Moderate alone — synergistic with GHRH |
| FDA history | None | ✅ FDA approved (pediatric) Best history | None |
| Cortisol/prolactin | Not affected | Not affected | Minimal — cleanest GHRP Safest |
| Best stacked with | Ipamorelin Classic combo | Ipamorelin | CJC-1295 or Sermorelin |
| Best for | Larger GH pulse, body comp | Conservative, FDA history | Clean GH pulse, minimal sides |
CJC-1295 in a Longevity Stack
CJC-1295 anchors the GH optimization layer — stacking naturally with compounds that amplify or complement its effects.
- +CJC-1295 + Ipamorelin — The definitive GH secretagogue combination. CJC-1295 is a GHRH analog — it signals the pituitary to prepare and release GH. Ipamorelin is a GHRP (ghrelin receptor agonist) — it amplifies the GH pulse through a completely different receptor pathway. Together they produce synergistically larger GH pulses than either alone — with Ipamorelin's clean profile (minimal cortisol, minimal prolactin) making it the ideal GHRP partner. The most widely used GH optimization combination in functional medicine.
- +CJC-1295 + Epithalon — Epithalon restores pineal-hypothalamic-pituitary axis coordination — the upstream regulatory system that coordinates the nocturnal GH pulse. CJC-1295 amplifies that pulse at the pituitary level. Together they address GH restoration from the regulatory (Epithalon, hypothalamic signaling) and stimulatory (CJC-1295, direct pituitary activation) angles simultaneously — particularly powerful for adults over 50 where both pineal function and pituitary responsiveness have declined.
- +CJC-1295 + GHK-Cu — CJC-1295 drives GH and IGF-1 elevation that stimulates collagen synthesis; GHK-Cu amplifies collagen deposition, gene regulation, and the structural tissue remodeling that follows. A powerful anti-aging combination for skin, connective tissue, and body composition — covering both the hormonal signaling (CJC-1295/IGF-1) and the cellular execution (GHK-Cu/gene regulation) of collagen restoration.
- +CJC-1295 + BPC-157 — The tissue repair amplification stack. BPC-157 activates angiogenesis and growth factor signaling at injury sites; CJC-1295-driven IGF-1 elevation provides the systemic anabolic environment that amplifies BPC-157's local repair effects. For athletes and active adults combining recovery from injury with body composition goals, this pairing addresses both the local (BPC-157) and systemic (CJC-1295/IGF-1) dimensions of tissue repair.
Frequently Asked Questions
Both are GHRH analogs with similar mechanisms — the primary differences are half-life and clinical history. Sermorelin has FDA history (pediatric approval) and a longer real-world safety track record. CJC-1295 without DAC produces a larger GH pulse amplitude due to its longer half-life. For first-time GH secretagogue users who prioritize a conservative, well-documented option, Sermorelin is often recommended. For those seeking maximum GH pulse amplitude and comfortable with a newer compound, CJC-1295 without DAC is the choice. Both are commonly stacked with Ipamorelin.
Sleep improvement is typically the earliest benefit — often noticeable within 2–4 weeks. Energy and recovery improvements follow at 4–8 weeks. Body composition changes — fat reduction and lean mass improvement — become measurable at 3–6 months. GH optimization is a long-game intervention; expect a minimum 6-month commitment for meaningful body composition results.
IGF-1 is the primary marker — it reflects overall GH status and gives you a baseline to track against. A comprehensive metabolic panel, fasting glucose, and fasting insulin are also recommended. Retest IGF-1 at 3 months and 6 months to assess response. Target IGF-1 range for most adults is 200–300 ng/mL — your provider will set specific targets based on your age and clinical picture. Avoid pushing IGF-1 above the upper limit of the age-appropriate reference range.
CJC-1295 without DAC preserves the natural feedback loop — when GH and IGF-1 reach appropriate levels, somatostatin is released to inhibit further GH secretion. This self-regulating mechanism prevents suppression of natural GH production. Standard cycling protocols (5 nights on / 2 off, with periodic longer breaks) are used as additional precaution. CJC-1295 with DAC, with its sustained GH elevation, has a less favorable profile on this question.
Look for: Certificate of Analysis confirming ≥98% purity by HPLC, correct molecular weight confirmation, clearly labeled variant (with or without DAC — do not accept unlabeled), lyophilized powder for injectable, cold-chain shipping. Confirm the supplier can distinguish between variants and provide batch-specific testing. The DAC vs no-DAC distinction is critical — a supplier who cannot clearly identify which variant they're selling is a red flag.
Free - Instant PDF download
This page is for educational purposes only and does not constitute medical advice. CJC-1295 is not FDA-approved for any indication. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol. Regular IGF-1 monitoring under physician supervision is standard practice for GH secretagogue protocols. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.
What Is SS-31?
The only peptide that concentrates directly at the inner mitochondrial membrane — addressing cellular energy failure at its source.
SS-31 (also known as Elamipretide, MTP-131, or Bendavia) is a synthetic tetrapeptide developed by Hazel Szeto and Peter Schiller at Weill Cornell Medicine. It belongs to the Szeto-Schiller peptide family — a class of compounds specifically engineered to target the inner mitochondrial membrane, where the cell's energy production machinery lives.
What makes SS-31 unique among peptides — and among all longevity compounds — is its extraordinary specificity. It doesn't simply support mitochondrial function broadly. It concentrates at cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane that is essential for the function of the electron transport chain complexes that produce ATP. By stabilizing cardiolipin, SS-31 directly restores the structural integrity of the energy production machinery itself.
SS-31 has progressed further through formal clinical development than almost any other peptide discussed in the longevity space — with Phase 2 and Phase 3 trials completed for heart failure with preserved ejection fraction (HFpEF), Barth syndrome, and mitochondrial myopathy. This clinical development history provides an unusually robust safety and efficacy evidence base.
Most mitochondrial supplements — CoQ10, PQQ, NAD+ precursors — support mitochondrial function from the outside. SS-31 works from the inside — it physically enters the mitochondrial membrane and stabilizes the cardiolipin that holds the electron transport chain complexes in their optimal configuration. This is a fundamentally different and more direct mechanism than any other mitochondrial support compound currently available.
How Does SS-31 Work?
Four mechanisms — all centered on the inner mitochondrial membrane.
Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. It acts as a structural scaffold for the electron transport chain complexes — holding them in the optimal configuration for ATP production. With age and oxidative stress, cardiolipin becomes oxidized and dysfunctional. SS-31 binds to cardiolipin and protects it from oxidation — directly preserving the structural integrity of the energy production machinery.
By stabilizing cardiolipin, SS-31 improves the efficiency of electron transport chain complexes I, III, and IV — the protein complexes that transfer electrons down the chain to ultimately produce ATP. Dysfunctional ETC complexes produce less ATP and more reactive oxygen species (ROS). SS-31 improves both — more ATP production and less oxidative byproduct.
SS-31's aromatic amino acid residues give it direct antioxidant properties at the site of ROS production — the inner mitochondrial membrane. By scavenging ROS precisely where they're generated, SS-31 prevents the oxidative damage that perpetuates mitochondrial dysfunction. This creates a positive feedback loop: less ROS damage → better cardiolipin integrity → more efficient ETC → less ROS production.
The mitochondrial membrane potential (ΔΨm) — the electrochemical gradient across the inner membrane — is the driving force for ATP synthesis. Dysfunctional mitochondria lose membrane potential, reducing ATP output. SS-31's cardiolipin stabilization and ETC optimization restore membrane potential — directly improving the cell's capacity to produce energy.
How SS-31 Reaches the Mitochondria
A unique charge-based targeting system delivers SS-31 precisely to the inner mitochondrial membrane.
What Is SS-31 Used For?
Wherever mitochondrial dysfunction drives disease or decline — SS-31 addresses the root cause.
- Brain Fog & Cognitive PerformanceThe brain's extraordinary energy demand makes it the first organ to suffer from mitochondrial dysfunction. SS-31's restoration of neuronal ATP production directly addresses the energy deficit underlying brain fog, cognitive slowing, and mental fatigue. The nasal spray delivery format provides particularly rapid CNS effect by bypassing the blood-brain barrier via the olfactory pathway.
- Fatigue & Energy RestorationMitochondrial dysfunction is increasingly recognized as a primary driver of chronic fatigue — including post-viral fatigue, Long COVID, and the age-related energy decline that begins in the 40s. SS-31 addresses this at the cellular energy production level rather than through stimulant mechanisms.
- Heart Failure & Cardiovascular HealthThe primary clinical application — SS-31 (as Elamipretide) has completed Phase 3 trials for heart failure with preserved ejection fraction (HFpEF). Cardiac muscle cells have an extraordinarily high mitochondrial density; SS-31's cardioprotective effects are among its most robustly documented in human clinical data.
- Muscle Function & Physical PerformanceSkeletal muscle mitochondrial dysfunction contributes to age-related muscle weakness and reduced exercise capacity. SS-31 has demonstrated improvements in muscle function and exercise tolerance in both clinical trials and real-world functional medicine use.
- Neuroprotection & Neurodegeneration PreventionMitochondrial dysfunction is increasingly recognized as a central feature of neurodegenerative conditions including Alzheimer's and Parkinson's. SS-31's mitochondrial protection mechanism is directly relevant to neuroprotection — particularly in the context of aging-related neurological decline prevention.
- Anti-Aging & LongevityMitochondrial dysfunction is one of the most consistent hallmarks of biological aging — identified in virtually every tissue type. SS-31's ability to restore mitochondrial function addresses aging at a fundamental cellular level, making it a meaningful anchor compound in any serious longevity protocol.
How to Use SS-31
Two delivery methods — each with distinct use cases and onset profiles.
Use nasal spray when the primary goal is cognitive performance or rapid CNS effect — the olfactory pathway delivers SS-31 directly to brain tissue within 15–30 minutes, bypassing the blood-brain barrier entirely. Use SubQ injection when the primary goal is systemic mitochondrial support — fatigue, cardiac function, muscle performance, or whole-body longevity. For comprehensive coverage, some practitioners use both — nasal for acute cognitive needs, SubQ for ongoing systemic maintenance.
SS-31 in a Mitochondrial Longevity Stack
SS-31 anchors the mitochondrial layer — the cellular energy foundation that all other longevity interventions depend on.
- +SS-31 + NAD+ — The most powerful mitochondrial combination. SS-31 restores the structural integrity of the electron transport chain via cardiolipin stabilization; NAD+ provides the electron carrier substrate that the ETC requires to function. Think of SS-31 as fixing the engine and NAD+ as providing the fuel. Together they address mitochondrial dysfunction from the structural (SS-31) and metabolic (NAD+) angles simultaneously — producing greater ATP restoration than either alone.
- +SS-31 + Semax — The definitive cognitive mitochondrial stack. SS-31 restores neuronal energy production at the mitochondrial level; Semax drives BDNF upregulation and neuroplasticity — the structural changes that better cognition requires. Energy without neuroplasticity produces a powered-up but unchanged brain. Neuroplasticity without energy produces structural potential with no fuel to realize it. Together they address both constraints on cognitive performance simultaneously.
- +SS-31 + Epithalon — Deep sleep is when mitochondrial repair and biogenesis peak — the overnight window when cells rebuild their energy production machinery. Epithalon restores the deep sleep architecture that makes this repair possible; SS-31 directly supports the mitochondrial function being repaired. A natural pairing for anyone experiencing both energy decline and sleep disruption — which is the majority of adults over 45.
- +SS-31 + BPC-157 — BPC-157 reduces systemic inflammation and gut-brain axis dysfunction; SS-31 addresses the mitochondrial energy deficit that inflammation perpetuates. Chronic inflammation is both a cause and consequence of mitochondrial dysfunction — BPC-157 addresses the inflammatory driver while SS-31 repairs the mitochondrial damage it causes. A meaningful combination for any chronic condition with both inflammatory and energy components.
Frequently Asked Questions
CoQ10 supports mitochondrial function from outside the inner membrane — it acts as an electron carrier in the ETC but doesn't address the structural cardiolipin dysfunction that underlies age-related mitochondrial decline. SS-31 enters the inner membrane itself and stabilizes cardiolipin — addressing the root structural cause. Additionally, CoQ10 bioavailability is notoriously poor, especially in older adults. SS-31 concentrates at the target site at 1000x the surrounding cellular concentration — a degree of targeting precision CoQ10 cannot achieve.
Via nasal spray for cognitive applications, many users report noticeable improvement in mental clarity and energy within 30–60 minutes. For systemic SubQ use, meaningful energy and fatigue improvements typically develop over 1–2 weeks of consistent dosing. Clinical trial data shows measurable improvements in cardiac function and exercise capacity within 4–8 weeks of consistent use.
SS-31 (Elamipretide) has been specifically studied in cardiac patients through Phase 2 and Phase 3 trials — making it one of the most extensively safety-evaluated peptides in clinical use. The Phase 3 PROGRESS-HF trial in heart failure patients showed a favorable safety profile. However, any cardiac patient considering SS-31 must discuss it with their cardiologist — cardiac conditions involve complex medication interactions and require physician oversight for any new intervention.
Research in aged animal models has shown that SS-31 can restore mitochondrial function to levels approaching those of younger animals — not just slow decline but meaningfully reverse functional deterioration. The mechanisms support this: cardiolipin oxidation is reversible with SS-31 intervention, and restored membrane potential enables the mitochondria to resume efficient ATP production. Whether this translates to full reversal in humans is still being established — but the mechanistic and animal evidence is genuinely encouraging.
Look for: Certificate of Analysis confirming ≥98% purity by HPLC, correct molecular weight confirmation (638.78 Da), lyophilized powder for injectable, correct pH formulation for nasal spray (pH 4–6), cold-chain shipping. Confirm the supplier can provide batch-specific testing documentation. SS-31 is technically demanding to synthesize correctly — quality variance between suppliers is significant.
This page is for educational purposes only and does not constitute medical advice. SS-31 (Elamipretide) is an investigational compound not approved by the FDA for any indication outside of clinical trials. Cardiac patients must consult their cardiologist before considering SS-31. Always work with a qualified healthcare provider before beginning any peptide protocol. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.
What Is KPV?
A tripeptide fragment of α-MSH — the body's primary anti-inflammatory hormone — that directly restores what chronic inflammation destroys.
KPV (Lysine-Proline-Valine) is a synthetic tripeptide derived from the C-terminal sequence of α-MSH (alpha-Melanocyte Stimulating Hormone) — the body's primary endogenous anti-inflammatory hormone. It represents the minimal active fragment of α-MSH responsible for its anti-inflammatory and immune-modulating properties.
α-MSH is produced by the pituitary gland and acts as a master regulator of the body's inflammatory response. In healthy individuals, α-MSH keeps inflammation appropriately controlled — resolving acute inflammation after injury or infection and preventing the chronic low-level inflammation that drives so many age-related diseases. In people with Chronic Inflammatory Response Syndrome (CIRS), mold illness, or certain chronic infections, α-MSH levels become critically depleted — leaving the inflammatory cascade with no brake.
KPV directly restores the α-MSH signaling pathway — providing the anti-inflammatory signal that depleted α-MSH can no longer deliver. This makes it not just an anti-inflammatory compound, but a targeted restoration of a specific failed biological control system.
In CIRS patients, a vicious cycle develops: depleted α-MSH allows MARCONS bacteria (Multiple Antibiotic Resistant Coagulase Negative Staph) to colonize the nasal passages. MARCONS actively produces enzymes that destroy α-MSH — further depleting the hormone that would otherwise clear them. KPV breaks this cycle by directly restoring the α-MSH pathway, creating an environment where MARCONS can be cleared and the inflammatory cascade can finally resolve.
How Does KPV Work?
Four mechanisms explain KPV's anti-inflammatory and immune-modulating effects.
KPV directly activates melanocortin receptors (MC1R, MC3R, MC4R) — the same receptors that α-MSH signals through. By providing this receptor activation, KPV restores the anti-inflammatory signaling cascade that depleted α-MSH can no longer deliver. This is the central mechanism that makes KPV uniquely relevant to CIRS and chronic inflammatory conditions.
KPV directly inhibits NF-κB — the master transcription factor that controls the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. NF-κB overactivation is a hallmark of chronic inflammatory conditions; KPV's ability to suppress it at the transcriptional level produces broad downstream anti-inflammatory effects.
KPV has shown direct protective effects on intestinal epithelial cells — reducing gut permeability, suppressing intestinal inflammation, and supporting the integrity of the gut lining. This mechanism makes KPV particularly relevant for the gut component of CIRS and for inflammatory bowel conditions where the intestinal barrier is compromised.
KPV modulates macrophage and dendritic cell activity — reducing the production of pro-inflammatory mediators while supporting appropriate immune function. This immune modulation is regulatory rather than suppressive — it normalizes dysregulated immune responses rather than broadly suppressing immunity.
Understanding Why KPV is Essential for CIRS
The MARCONS-α-MSH destruction cycle — and how KPV breaks it.
What Is KPV Used For?
Targeted applications for chronic inflammatory conditions — with CIRS as the primary indication.
- CIRS & Mold IllnessThe primary application. KPV is the α-MSH restoration anchor of the Shoemaker CIRS protocol — used alongside Thymosin Alpha-1 for comprehensive immune rebalancing. The 4-month minimum duration reflects the time required to fully restore α-MSH pathway function and break the MARCONS-α-MSH destruction cycle.
- Inflammatory Bowel DiseaseKPV's direct gut epithelial protection and NF-κB inhibition make it a meaningful intervention for Crohn's disease and ulcerative colitis — conditions characterized by exactly the kind of NF-κB-driven intestinal inflammation that KPV targets. Oral delivery is particularly relevant for IBD given its direct contact with the gut lining.
- Leaky Gut & Gut PermeabilityBeyond IBD, KPV supports gut barrier integrity broadly — relevant for the subclinical gut permeability that contributes to systemic inflammation, food sensitivities, and immune dysregulation in many chronic health conditions.
- Long COVID & Post-Viral SyndromePost-viral syndromes — including Long COVID — increasingly fit the CIRS framework, with many patients showing depleted α-MSH and the same biotoxin-driven inflammatory pattern. KPV is being applied by CIRS-trained practitioners to Long COVID with meaningful clinical results.
- Chronic Lyme & Co-infectionsBorrelia and associated co-infections drive the same HLA-DR-mediated biotoxin retention and α-MSH depletion pattern as mold illness. KPV addresses the inflammatory cascade component of chronic Lyme regardless of whether active infection is still present.
- General Chronic Inflammation & InflammagingFor adults with elevated inflammatory markers (hsCRP, TGF-β1) without a clear CIRS diagnosis, KPV's NF-κB inhibition and immune modulation provide meaningful anti-inflammaging support as part of a broader longevity protocol.
How to Use KPV
Duration is the most critical protocol variable — 4 months minimum is non-negotiable for CIRS applications.
Do not cycle off KPV early in CIRS protocols. The most common practitioner error in CIRS treatment is discontinuing KPV before the α-MSH pathway is fully restored — which allows MARCONS to re-establish and the destruction cycle to resume from scratch. The 4-month minimum is not arbitrary — it reflects the biological time required to restore α-MSH signaling to a level that can self-sustain. Work with a CIRS-trained practitioner to determine your specific duration based on serial α-MSH lab testing.
KPV in a Chronic Inflammation Stack
KPV anchors the immune regulation layer — combined with compounds that address the tissue damage inflammation leaves behind.
- +KPV + Thymosin Alpha-1 — The definitive CIRS combination. Thymosin Alpha-1 restores appropriate immune regulation — normalizing the dysregulated TGF-β1 driven inflammatory cascade. KPV restores the α-MSH pathway and breaks the MARCONS cycle. Together they address CIRS from two distinct but complementary immune angles — Thymosin Alpha-1 at the TGF-β1 / T-cell regulation level, KPV at the α-MSH / melanocortin receptor level. This is the anchor combination of the Shoemaker Protocol peptide approach.
- +KPV + BPC-157 — CIRS reliably damages gut integrity — and gut permeability is both a consequence and driver of ongoing systemic inflammation. BPC-157 repairs the gut lining, reduces intestinal inflammation, and addresses the leaky gut component of CIRS that keeps the inflammatory cycle running. KPV provides the immune modulation; BPC-157 repairs the structural gut damage. A complementary and synergistic combination for any chronic inflammatory condition with a gut component.
- +KPV + Epithalon — CIRS patients almost universally experience disrupted restorative sleep — which amplifies the inflammatory cascade. Epithalon restores deep sleep and REM through pineal gland support, which also supports the same α-MSH-related pathway disrupted by CIRS. Additionally addresses the accelerated telomere shortening driven by chronic systemic inflammation — a meaningful longevity consideration for long-term CIRS sufferers.
- +KPV + NAD+ — Chronic inflammation is one of the primary drivers of NAD+ depletion through PARP overactivation. As CIRS-driven inflammation is reduced by KPV, NAD+ restoration becomes more efficient — less is consumed by damage repair and more is available for energy production and sirtuin activity. A meaningful metabolic combination for CIRS recovery.
Frequently Asked Questions
The 4-month minimum reflects the biological time required to restore α-MSH pathway function to a level that can self-sustain after MARCONS clearance. α-MSH restoration is not a switch that flips — it's a gradual reestablishment of receptor sensitivity and signaling cascade function. Stopping early leaves the pathway partially restored, allowing MARCONS to re-establish and the destruction cycle to resume. This is the single most common protocol error in CIRS treatment — and the most consequential.
Both are used clinically — the choice depends on the primary application. For gut-specific inflammation (IBD, leaky gut), oral delivery provides direct contact with intestinal tissue and is generally preferred. For systemic CIRS protocols, subcutaneous injection provides more reliable systemic bioavailability. Some practitioners use both simultaneously — oral for gut coverage, SubQ for systemic effect. Discuss delivery preferences with your CIRS-trained provider.
For CIRS protocols — yes, ideally. Baseline α-MSH testing confirms the deficiency that KPV is addressing and gives you a marker to track restoration against. Retesting at 4 months guides the decision about whether to continue, adjust dose, or transition to maintenance. For general gut inflammation or anti-inflammaging use without a CIRS diagnosis, baseline testing is less critical but still provides useful information.
Yes — KPV's anti-inflammatory mechanisms are relevant beyond formal CIRS. Its NF-κB inhibition and gut epithelial protection make it meaningful for IBD, leaky gut, Long COVID, post-viral syndromes, and general inflammaging protocols. The CIRS-specific 4-month minimum applies primarily to the α-MSH restoration goal — for other applications, protocol duration is guided by the specific condition and clinical response.
For CIRS: α-MSH (primary marker), TGF-β1, C4a, MMP-9. For general inflammation: hsCRP (high sensitivity), ESR. For gut protocols: calprotectin (intestinal inflammation marker), zonulin (gut permeability). Retest at 8–12 weeks to assess response — or at 4 months for CIRS-specific α-MSH restoration tracking.
One-time purchase — instant PDF download
This page is for educational purposes only and does not constitute medical advice. KPV is not FDA-approved for any indication. CIRS requires diagnosis and management by a qualified, trained physician. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol — particularly for CIRS where improper protocol sequencing can worsen outcomes. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.
What Is Selank?
A synthetic anxiolytic neuropeptide that calms without sedating — and builds the neurological foundation for better stress resilience over time.
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Russia — the same institution that developed Semax. It is derived from tuftsin, a naturally occurring tetrapeptide produced by the spleen that plays a role in immune regulation and has known effects on the central nervous system. Selank extends tuftsin with an additional tripeptide sequence (Pro-Gly-Pro) that increases its stability and CNS penetrance — the same modification used in Semax.
Selank has been approved as a prescription anxiolytic medication in Russia since the early 2000s, where it is used for generalized anxiety disorder, neurasthenia, and cognitive impairment associated with anxiety. Its clinical track record spans over three decades of use in Russian psychiatry and neurology.
What distinguishes Selank from conventional anxiolytics — particularly benzodiazepines — is its mechanism. Selank does not cause sedation, dependency, tolerance, or the cognitive blunting that characterizes benzodiazepine use. It reduces anxiety through neuroprotective and neuroplasticity-supporting pathways rather than broad GABAergic suppression — producing what users consistently describe as calm, clear-headed focus rather than sedated relief.
Benzodiazepines reduce anxiety by broadly enhancing GABA activity — effectively suppressing central nervous system activity across the board. The result is anxiety relief accompanied by sedation, cognitive impairment, and with repeated use, dependency and withdrawal. Selank modulates GABA receptors more selectively while simultaneously supporting BDNF and enkephalin systems — producing anxiety relief without the cognitive cost, dependency risk, or rebound anxiety that characterizes benzo use.
How Does Selank Work?
Four mechanisms explain Selank's anxiolytic, neuroprotective, and cognitive effects.
Selank modulates GABAergic transmission — the primary inhibitory neurotransmitter system that benzodiazepines target. Unlike benzos which broadly enhance GABA activity, Selank's modulation is more selective and regulatory — reducing anxiety-driven neural overactivation without the global CNS suppression that causes sedation and cognitive impairment.
Selank increases BDNF expression — supporting neuroplasticity, the formation of new neural connections, and the long-term structural changes in anxiety-regulating circuits that make anxiety reduction durable rather than temporary. This is the mechanism that separates Selank from symptomatic anxiolytics — it works on the underlying neural architecture, not just the symptoms.
Selank inhibits enkephalinase — the enzyme that breaks down enkephalins (endogenous opioid peptides involved in stress response and mood regulation). By preserving enkephalin levels, Selank supports the body's natural stress-buffering system and contributes to the mood-lifting effects reported by users alongside anxiety reduction.
Derived from tuftsin — an immunoregulatory peptide — Selank retains immune-modulating properties. It has shown effects on cytokine balance and immune function, which is relevant given the increasingly recognized connection between neuroinflammation, immune dysregulation, and anxiety disorders.
What Is Selank Used For?
From generalized anxiety to cognitive performance — Selank addresses the nervous system from the calming end of the spectrum.
- Generalized Anxiety DisorderThe primary clinical application in Russia. Selank has demonstrated meaningful anxiolytic efficacy in clinical trials for GAD — comparable to benzodiazepines in symptom reduction without the sedation, dependency, or cognitive impairment. Particularly useful for chronic anxiety where long-term benzodiazepine use is not appropriate.
- Situational & Performance AnxietyFor acute anxiety in high-stakes situations — presentations, social events, medical procedures — Selank provides rapid anxiolytic relief (onset ~20 minutes) without impairing cognitive function or motor performance. Unlike benzos, Selank does not impair the clear thinking needed to perform well in the situation causing the anxiety.
- Cognitive Performance Under StressAnxiety-driven cognitive load — the mental static of worry and rumination — is one of the most common causes of reduced cognitive performance. By clearing that static without sedation, Selank frequently produces a paradoxical improvement in focus and cognitive clarity alongside anxiety reduction.
- Depression & Mood SupportThrough its enkephalin stabilization and BDNF upregulation mechanisms, Selank has demonstrated antidepressant-adjacent effects — particularly relevant for the depression that commonly accompanies chronic anxiety. Not a primary antidepressant, but a meaningful mood-supporting compound in the context of anxiety treatment.
- Benzodiazepine Tapering SupportAn increasingly recognized use — Selank's GABAergic modulation can support the transition off benzodiazepines by providing partial anxiolytic coverage during the tapering process. This application requires close physician supervision and should never be attempted without professional guidance.
- Neuroinflammation & Immune RegulationSelank's immune-modulating properties — inherited from its tuftsin parent — make it relevant for anxiety presentations with a neuroinflammatory component. The anxiety-inflammation connection is increasingly recognized in functional medicine, and Selank addresses both dimensions simultaneously.
The Russian Neuropeptide Duo
Selank and Semax are the two most clinically established Russian neuropeptides — different profiles, complementary effects.
| Feature | Selank | Semax |
|---|---|---|
| Primary effect | Anxiolytic — calming Evening | Activating — cognitive performance Morning |
| BDNF effect | ✅ Moderate upregulation | ✅ Strong upregulation — up to 800% |
| Anxiety | ✅ Primary indication Selank wins | ⚠️ Can increase anxiety at high doses |
| Focus & activation | ⚠️ Calming — less activating | ✅ Strong activation Semax wins |
| Dependency risk | ✅ None reported | ✅ None reported |
| Sedation | ✅ None — calming without sedation | ✅ None |
| Best timing | Evening or as needed for anxiety | Morning — cognitive performance |
| Best together? | ✅ YES — Semax AM + Selank PM is the classic combination | |
InformedPeptides may earn a commission on purchases made through affiliate links on this page. This never influences our editorial content or recommendations. We only recommend sources we have independently evaluated.
How to Use Selank
Flexible dosing — as needed for acute anxiety or daily for ongoing anxiolytic and neuroprotective benefits.
While Selank has no reported dependency risk, combining it with benzodiazepines, barbiturates, or other GABAergic medications requires physician oversight due to additive CNS effects. Anyone currently taking psychiatric medications — SSRIs, SNRIs, antipsychotics, mood stabilizers — should not add Selank without consulting their prescribing physician. Selank is not a replacement for professional mental health treatment.
Selank in a Cognitive & Mood Stack
Selank anchors the anxiety and mood regulation layer of a complete cognitive longevity protocol.
- +Selank + Semax — The definitive Russian neuropeptide pairing. Semax in the morning for cognitive activation, BDNF upregulation, and focus. Selank in the evening for anxiety reduction, neural recovery, and enkephalin support. Together they address the full cognitive-emotional spectrum — performance during the day, restoration at night. The most widely used neuropeptide combination in functional medicine.
- +Selank + Epithalon — Selank reduces daytime anxiety and supports mood; Epithalon restores the deep sleep architecture that anxiety chronically disrupts. The anxiety-sleep disruption cycle is one of the most damaging feedback loops in mental health — this combination addresses both ends simultaneously. Epithalon's pineal restoration normalizes melatonin and cortisol rhythms that anxiety dysregulates.
- +Selank + BPC-157 — BPC-157 works along the gut-brain axis via the vagus nerve and reduces systemic inflammation that contributes to neuroinflammatory anxiety. Selank addresses the CNS anxiety presentation directly. Together they cover both the peripheral (gut-brain, inflammation) and central (GABA, BDNF) dimensions of anxiety — particularly relevant for anxiety with significant gut symptoms.
- +Selank + NAD+ — NAD+ restores the mitochondrial energy production that anxiety chronically depletes. Chronic anxiety is metabolically expensive — it maintains a sustained stress response that burns through cellular energy reserves. NAD+ replenishment combined with Selank's anxiety reduction creates a more favorable neurological and metabolic environment for recovery.
Frequently Asked Questions
No dependency or withdrawal syndrome has been reported in the clinical literature for Selank — including in studies specifically designed to assess this risk. This is one of the most significant advantages over benzodiazepines. The mechanism difference is key: benzos cause receptor downregulation and physical dependency; Selank's GABAergic modulation is more regulatory and does not appear to produce the same adaptation. Standard cycling protocols (4–8 weeks on, break) are still recommended as good practice.
Via nasal spray, anxiolytic effects are typically noticeable within 15–30 minutes. The effect is described as a calming of mental static and reduction in anxiety intensity — not sedation. For acute situational anxiety, administer 20–30 minutes before the anxiety-provoking situation. For daily anxiolytic maintenance, effects build over the first 1–2 weeks of consistent use.
Selank is not a replacement for prescribed psychiatric medications — and should never be used to self-discontinue medications without physician guidance. It may serve as a complement to psychiatric treatment or as part of a tapering protocol under close medical supervision. Anyone considering using Selank in the context of existing psychiatric medication must discuss this with their prescribing physician.
They are the same compound — Selank is the Russian name; Selink is an alternative transliteration used in some Western markets and functional medicine contexts. You may see both names used interchangeably. When evaluating suppliers, confirm the compound is the tuftsin analog heptapeptide regardless of the name used.
Look for: Certificate of Analysis confirming ≥98% purity by HPLC, correct pH-balanced nasal formulation (pH 4–6), clearly stated concentration per spray, cold-chain shipping. Confirm the compound is the full tuftsin analog sequence. Avoid: no CoA available, unusually low pricing, pre-mixed solutions without pH confirmation, suppliers who cannot distinguish between Selank and Semax.
This page is for educational purposes only and does not constitute medical advice. Selank is an approved prescription medication in Russia and a research compound in the US and EU. It is not a replacement for professional mental health treatment. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol — especially if currently taking psychiatric medications. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.
What Is TB-500?
The systemic tissue repair peptide — where BPC-157 works locally, TB-500 works throughout the entire body.
TB-500 is a synthetic version of a naturally occurring peptide fragment derived from Thymosin Beta-4 (Tβ4) — a protein found in virtually every cell in the human body. It consists of the active sequence of Tβ4 responsible for its tissue repair and anti-inflammatory properties, specifically the amino acid sequence LKKTETQ (actin-binding domain).
Thymosin Beta-4 is one of the most abundant proteins in mammalian cells and plays a critical role in cell migration, wound healing, and tissue repair. When tissue is damaged, Tβ4 is released from cells to orchestrate the repair response. TB-500 delivers this repair signal in concentrated, bioavailable form — amplifying what the body already does naturally.
The key distinction between TB-500 and BPC-157 — the other major healing peptide — is their scope of action. BPC-157 tends to work locally at or near the site of administration. TB-500 is systemically distributed — it travels throughout the body and promotes healing wherever it's needed, not just at the injection site. This makes them powerfully complementary rather than redundant.
Think of BPC-157 as a precision repair tool — highly effective at the local level, particularly for gut healing, tendon repair at a specific site, and localized injury. TB-500 is the systemic repair signal — it circulates throughout the body and promotes healing wherever tissue damage exists. Used together, they cover both local precision and systemic breadth — which is why the BPC-157 + TB-500 stack is one of the most consistently recommended combinations in functional medicine.
How Does TB-500 Work?
Four mechanisms explain TB-500's broad systemic repair and anti-inflammatory effects.
TB-500's primary mechanism is binding to actin — the protein that forms the cytoskeleton of cells. By regulating actin polymerization, TB-500 promotes cell migration to injury sites, accelerating the recruitment of the cells needed for tissue repair and wound healing.
Like BPC-157, TB-500 promotes angiogenesis — the formation of new blood vessels at injury sites. New vasculature delivers oxygen, nutrients, and repair cells to damaged tissue. TB-500's angiogenic effect is one of the primary reasons it accelerates healing in tissues with poor blood supply, like tendons and cartilage.
TB-500 reduces pro-inflammatory cytokine production — particularly relevant for chronic injuries where persistent inflammation impairs healing rather than driving it. Unlike anti-inflammatories that simply block the inflammatory response, TB-500 modulates it — reducing damaging chronic inflammation while preserving the acute inflammatory signals needed for repair.
TB-500 activates progenitor cells and promotes their differentiation into specialized repair cells — including the cardiac progenitor cells that have made it a subject of cardiovascular repair research. This stem cell activation mechanism gives TB-500 regenerative capacity beyond simple wound healing.
What Is TB-500 Used For?
Systemic tissue repair across multiple organ systems — with particular strength in musculoskeletal and cardiovascular applications.
- Tendon & Ligament RepairOne of the most common applications. TB-500's angiogenic and cell migration mechanisms are particularly effective for tendons and ligaments — connective tissues notoriously difficult to heal due to poor blood supply. Users and practitioners consistently report accelerated recovery from tendinopathy, rotator cuff injuries, and ligament damage.
- Muscle Recovery & Injury RepairTB-500 accelerates muscle repair after tears, strains, and overuse injuries. The stem cell activation mechanism adds a regenerative dimension beyond simple healing — promoting the formation of new muscle fiber rather than just scar tissue.
- Chronic Injury & InflammationFor athletes and active adults dealing with persistent injuries that haven't responded to standard treatment, TB-500's anti-inflammatory and angiogenic effects address the core biology of why chronic injuries stall. It breaks the cycle of inflammation that prevents healing from completing.
- Cardiovascular Tissue RepairTB-500's cardiac progenitor cell activation has made it a subject of serious cardiovascular research — with studies showing potential for cardiac tissue repair after myocardial injury. This remains an emerging research area but represents one of the more compelling future applications of this peptide class.
- Neurological RecoveryTB-500 has shown neuroprotective effects and the ability to support neural repair — including improved outcomes in traumatic brain injury models. The combination of anti-inflammation, angiogenesis, and stem cell activation creates a favorable environment for neurological healing.
- Anti-Aging & InflammagingTB-500's systemic anti-inflammatory properties make it relevant to any longevity protocol targeting inflammaging — the chronic low-level inflammation that drives biological aging. Combined with BPC-157, it addresses the inflammatory burden of aging from both local and systemic angles.
Understanding the Difference
The two most important healing peptides — different mechanisms, complementary effects.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Scope of action | Systemic — whole body Broad | Local — site of administration |
| Primary mechanism | Actin regulation, cell migration | Angiogenesis, growth factor signaling |
| Gut healing | ⚠️ Limited | ✅ Strong — primary application BPC wins |
| Tendon repair | ✅ Strong — systemic | ✅ Strong — local |
| Cardiovascular repair | ✅ Strong research base TB wins | ⚠️ Limited |
| Neurological repair | ✅ Emerging evidence | ✅ Gut-brain axis |
| Injection frequency | 2x weekly Less frequent | Daily or 2x daily |
| Best together? | ✅ YES — BPC-157 + TB-500 is the gold standard healing stack | |
How to Use TB-500
Loading and maintenance phases — less frequent dosing than most healing peptides.
TB-500 typically comes as a lyophilized (freeze-dried) powder in 2mg or 5mg vials. Reconstitute with bacteriostatic water — add slowly along the vial wall, do not shake. Store reconstituted TB-500 refrigerated and use within 4–6 weeks. Always verify purity via Certificate of Analysis before use.
TB-500 in a Recovery & Longevity Stack
TB-500 anchors the systemic repair layer of any serious healing or longevity protocol.
- +TB-500 + BPC-157 — The definitive healing stack. TB-500 delivers systemic repair signaling throughout the body; BPC-157 provides precision local healing with particular strength in gut, tendon, and nerve repair. Together they cover the complete healing picture — no single peptide does what both do in combination. The most consistently recommended pairing in functional medicine for injury recovery.
- +TB-500 + GHK-Cu — A comprehensive tissue regeneration stack. TB-500 drives cell migration and angiogenesis at injury sites; GHK-Cu amplifies the collagen deposition and remodeling phase that follows. Particularly powerful for skin, connective tissue, and wound healing — covering both the repair initiation (TB-500) and the structural rebuilding (GHK-Cu) phases.
- +TB-500 + Epithalon — An anti-aging combination addressing both systemic inflammation and telomere maintenance. TB-500 reduces the chronic inflammatory burden that accelerates telomere shortening; Epithalon maintains the telomere length that determines cellular lifespan. A meaningful longevity pairing for anyone using TB-500 beyond pure injury recovery.
- +TB-500 + NAD+ — TB-500 drives tissue repair; NAD+ provides the cellular energy that makes repair processes possible. Mitochondrial dysfunction — addressed by NAD+ restoration — is one reason healing slows with age. This combination ensures the energy substrate is available to support the repair signaling that TB-500 initiates.
Frequently Asked Questions
Not exactly. Thymosin Beta-4 (Tβ4) is the full naturally occurring protein. TB-500 is a synthetic version of the active fragment of Tβ4 — specifically the actin-binding sequence responsible for most of Tβ4's healing and repair properties. TB-500 is easier to synthesize, more stable, and more bioavailable than full Tβ4 — making it the practical choice for therapeutic use. The effects are closely comparable because the active fragment drives the primary mechanisms.
Many users report noticeable improvement in injury symptoms within 1–2 weeks of starting a loading protocol. Significant tissue repair typically occurs over the full 4–6 week loading phase. Results depend heavily on the severity and chronicity of the injury — acute injuries generally respond faster than chronic degeneration that has been present for months or years.
This is a common concern given Tβ4's role in cell migration and angiogenesis — mechanisms that can theoretically support tumor growth. The current evidence does not support TB-500 as a cancer promoter at therapeutic doses in healthy individuals, and Tβ4 has actually shown anti-tumor properties in some research contexts. However, anyone with a personal or family history of cancer should discuss this question specifically with their oncologist before considering TB-500. This is not a compound to use without physician oversight.
Most practitioners use TB-500 in defined courses — 4–6 week loading phases followed by maintenance dosing or breaks. Long-term continuous use beyond 3–4 months is less common and less well-studied. For ongoing injury prevention and anti-aging purposes, many practitioners cycle TB-500 — 6 weeks on, 4–6 weeks off — rather than continuous administration.
Look for: Certificate of Analysis (CoA) confirming ≥98% purity by HPLC, lyophilized powder (not pre-mixed liquid), correct molecular weight confirmation, cold-chain shipping, and a verifiable supplier. Avoid: no CoA available, pre-reconstituted liquid TB-500, unusually low pricing, and suppliers who cannot provide batch-specific testing documentation.
Free Guide — Instant PDF download
This page is for educational purposes only and does not constitute medical advice. TB-500 is not FDA-approved for any indication. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol. Anyone with a history of cancer should consult their oncologist before considering TB-500. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.
What Is AOD 9604?
The fat-burning fragment of Human Growth Hormone — isolated to deliver metabolic benefits without the side effects of full HGH.
AOD 9604 (Advanced Obesity Drug 9604) is a synthetic peptide consisting of amino acids 177–191 from the C-terminal region of Human Growth Hormone. It was originally developed by Monash University in Australia specifically to isolate the fat-metabolizing properties of HGH — without the insulin resistance, tissue overgrowth, and other side effects associated with full HGH administration.
The key insight behind AOD 9604 is that HGH's lipolytic (fat-burning) activity is contained within a specific fragment of the molecule — and that fragment can be isolated and used independently. The result is a peptide that activates the same fat-burning pathways as HGH while leaving the growth-promoting and insulin-disrupting mechanisms of full HGH entirely untouched.
AOD 9604 completed Phase 2 clinical trials for obesity treatment — giving it one of the more advanced clinical development histories of any peptide currently used in the functional medicine space. While it was ultimately not commercialized as a pharmaceutical, the clinical data generated provides a meaningful evidence base for its safety and efficacy profile.
Full HGH stimulates fat burning but also promotes tissue growth, can cause insulin resistance, and suppresses natural GH production via negative feedback. AOD 9604 delivers the lipolytic benefits of HGH with none of these concerns — it does not affect IGF-1 levels, does not promote abnormal tissue growth, and does not interfere with insulin sensitivity. It's the targeted extraction of one specific HGH mechanism.
How Does AOD 9604 Work?
Four mechanisms explain AOD 9604's fat loss and metabolic effects.
AOD 9604 directly stimulates lipolysis — the breakdown of stored fat into free fatty acids for energy use. It activates beta-3 adrenergic receptors in fat tissue, mimicking the fat-burning signal of HGH without requiring full HGH administration. This is the primary mechanism driving its fat loss effects.
Simultaneously, AOD 9604 inhibits lipogenesis — the process by which the body converts carbohydrates and other substrates into new fat stores. This dual action (more fat burning + less fat storage) creates a more favorable metabolic environment than lipolysis stimulation alone.
An unexpected finding from AOD 9604 research is its effect on cartilage and bone tissue. Studies have demonstrated regenerative effects on osteoarthritis-damaged cartilage — making AOD 9604 relevant beyond pure fat loss, particularly for aging adults dealing with joint degeneration alongside metabolic concerns.
Unlike full HGH, AOD 9604 does not stimulate IGF-1 production and does not cause insulin resistance. This is the critical safety advantage — the metabolic concerns that limit long-term HGH use are absent with AOD 9604, making it appropriate for extended protocols.
What Is AOD 9604 Used For?
From targeted fat loss to joint health — AOD 9604 has a broader application profile than its name suggests.
- Targeted Fat Loss & Body CompositionThe primary application. AOD 9604 is particularly effective for stubborn fat deposits — the visceral and subcutaneous fat that resists diet and exercise interventions. Particularly relevant for adults experiencing the age-related metabolic slowdown that makes fat loss progressively harder after 40.
- Metabolic Rate EnhancementBeyond direct lipolysis, AOD 9604 supports overall metabolic rate — relevant for anyone experiencing the metabolic deceleration associated with aging, thyroid changes, or reduced physical activity.
- Joint & Cartilage HealthThe cartilage regeneration data from AOD 9604 studies makes it a relevant compound for osteoarthritis, joint pain, and age-related cartilage degeneration — particularly when these concerns coincide with body composition goals.
- GLP-1 ComplementAOD 9604 is increasingly used alongside GLP-1 medications (semaglutide, tirzepatide) — where GLP-1 drives appetite suppression and AOD 9604 amplifies the lipolytic response. A synergistic combination for those already on a GLP-1 protocol seeking to maximize fat loss outcomes.
- Post-Diet Metabolic MaintenanceAfter significant weight loss, metabolic adaptation (the "set point" response) makes maintaining results difficult. AOD 9604 supports the metabolic rate needed to sustain body composition improvements during the maintenance phase.
Why AOD 9604 Instead of HGH?
The targeted approach beats the broad approach for most adults seeking fat loss without the risks of full HGH.
| Feature | AOD 9604 | Full HGH |
|---|---|---|
| Fat burning (lipolysis) | ✅ Strong — primary mechanism AOD wins | ✅ Yes — but indirect |
| IGF-1 stimulation | ✅ None — no growth effects Safer | ❌ Significant — drives tissue growth |
| Insulin sensitivity | ✅ Not affected Safer | ❌ Can cause insulin resistance |
| Natural GH suppression | ✅ Does not suppress Safer | ❌ Suppresses natural production |
| Joint/cartilage benefit | ✅ Demonstrated | ⚠️ Some benefit but via IGF-1 |
| Cost | ✅ Significantly lower Accessible | ❌ High — $500–2000+/month |
| Legal status (US) | Research compound — off-label | Schedule III controlled substance |
| Best for | Fat loss, body comp, joint health | Clinical GH deficiency |
InformedPeptides may earn a commission on purchases made through affiliate links on this page. This never influences our editorial content or recommendations. We only recommend sources we have independently evaluated.
How to Use AOD 9604
Two primary protocols — fasted timing is critical for both.
AOD 9604 must be administered in a fasted state — food intake, particularly carbohydrates, blunts the lipolytic response significantly. Administer at least 30–60 minutes before eating, and ideally 2+ hours after your last meal. Morning fasted injection is the most common and reliable protocol.
AOD 9604 in a Body Composition Stack
AOD 9604 stacks naturally with compounds that address the metabolic and structural dimensions of body composition.
- +AOD 9604 + Semaglutide / Tirzepatide — The most powerful fat loss combination available. GLP-1 medications suppress appetite and reduce caloric intake; AOD 9604 amplifies the lipolytic response to ensure fat is the primary fuel source during the caloric deficit. Together they address both the intake (GLP-1) and expenditure (AOD 9604) sides of the energy equation.
- +AOD 9604 + 5-Amino-1MQ — A targeted metabolic stack. 5-Amino-1MQ inhibits NNMT to preserve NAD+ and reduce fat cell formation; AOD 9604 directly stimulates lipolysis. Together they address fat loss at the cellular energy level (5-Amino-1MQ) and the hormonal signaling level (AOD 9604) simultaneously.
- +AOD 9604 + BPC-157 — For adults whose body composition goals are complicated by joint pain or injury. AOD 9604 drives the fat loss; BPC-157 repairs the tissue damage that makes exercise difficult. Addressing both barriers simultaneously produces better adherence and better outcomes than tackling either alone.
- +AOD 9604 + Sermorelin — AOD 9604 provides targeted fat-burning from the HGH C-terminal fragment; Sermorelin restores the full pulsatile GH release that drives body composition, sleep, and recovery. Together they address GH-related body composition from two complementary angles without the risks of full HGH supplementation.
Frequently Asked Questions
Results vary significantly based on diet, exercise, and individual metabolic factors. Clinical trials showed meaningful fat reduction compared to placebo over 12-week periods. AOD 9604 is not a substitute for caloric management — it amplifies fat loss in the context of a reasonable nutrition and exercise protocol. Expect meaningful body composition improvement over 12–16 weeks, particularly in stubborn areas like visceral and lower body fat.
No — this is one of AOD 9604's key advantages over full HGH. Clinical trials specifically confirmed that AOD 9604 does not affect blood glucose or insulin sensitivity, making it appropriate for use in patients with metabolic syndrome, pre-diabetes, or those on GLP-1 medications where insulin dynamics are already being managed.
Oral formulations of AOD 9604 exist and are used clinically, though subcutaneous injection produces more reliable bioavailability. Oral AOD 9604 has some evidence of efficacy — particularly for joint/cartilage applications — but the lipolytic response is generally considered stronger with injectable administration. Discuss delivery preferences with your provider.
Phase 2 clinical trials found AOD 9604 to be well-tolerated with a clean safety profile over the trial duration. Unlike full HGH, there are no concerns about IGF-1 elevation, insulin resistance, or natural GH suppression with extended use. Standard practice is 12–16 week protocols with periodic breaks, though some practitioners use longer continuous protocols under monitoring.
This page is for educational purposes only and does not constitute medical advice. AOD 9604 is not FDA-approved for any indication. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.